Fingolimod
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB08868 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 22 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | borderline ovarian serous tumor | KG + DL |
| 2 | ovarian papillary cystadenoma | KG + DL |
| 3 | malignant ovarian Brenner tumor | KG + DL |
| 4 | rete ovarii cystadenoma | KG + DL |
| 5 | serous neoplasm | KG + DL |
| 6 | ovarian mucinous cystadenofibroma | KG + DL |
| 7 | mucinous ovarian cystadenoma | KG + DL |
| 8 | ovarian benign neoplasm | KG + DL |
| 9 | ovarian surface papilloma | KG + DL |
| 10 | Immunoerythromyeloid hypoplasia | KG + DL |
| 11 | dermatofibrosarcoma protuberans | KG + DL |
| 12 | non-severe combined immunodeficiency | KG + DL |
| 13 | fibroblastic neoplasm | KG + DL |
| 14 | mucinous ovarian cancer | KG + DL |
| 15 | heart fibrosarcoma | KG + DL |
| 16 | severe combined immunodeficiency (disease) | KG + DL |
| 17 | conventional fibrosarcoma | KG + DL |
| 18 | kidney fibrosarcoma | KG + DL |
| 19 | low grade fibromyxoid sarcoma | KG + DL |
| 20 | T-B+ severe combined immunodeficiency due to CD45 deficiency | KG + DL |
| 21 | ovarian clear cell cancer | KG + DL |
| 22 | lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.